TheraCea Pharma LLC
TheraCea will commercialize new methods for rapid preparation of Fluorine-18 labeled biomolecules. These radio-labeled compounds are used as contrast agents for Positron Emission Tomography (PET). Current laborious, time-consuming compounding and purification methods reduce the effectiveness of these agents due to short half-life of the F-18 molecule. This faster, simplified preparation method does not require advanced radiochemistry expertise on-site, thereby increasing accessibility and expanding the market for PET agents and PET imaging.